LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Beckman Coulter Acquires AI-Based Clinical Decision Support Company StoCastic

By LabMedica International staff writers
Posted on 12 Oct 2022
Image: The TriageGo decision support tool seamlessly integrates EHR systems and routine ED workflow (Photo courtesy of StoCastic)
Image: The TriageGo decision support tool seamlessly integrates EHR systems and routine ED workflow (Photo courtesy of StoCastic)

Beckman Coulter, Inc. (Brea, CA, USA) has acquired StoCastic, LLC (Towson, MD, USA), an artificial intelligence (AI) company that provides evidence-based decision support for hospital emergency departments (EDs). StoCastic's TriageGo will be a cornerstone of Beckman Coulter's AI enabled Clinical Decision Support (CDS) portfolio, a growing field that aims to further improve patient care by leveraging data-driven insights for clinicians and optimize clinical decision making.

StoCastic's TriageGo decision support tool seamlessly integrates Electronic Health Record systems and routine ED workflow. The purpose of ED triage is to differentiate patients' criticality, yet 60-70% of all patients in the U.S. are triaged to an ambiguous Emergency Severity Index Level 3, meaning the projected course of care is uncertain. TriageGo has been shown to reduce decision making times in the ED, including decreasing door-to-clinical decision time by 20-30 minutes, door-to-ICU times by 40-80 minutes and door-to-ED departure for those having emergency surgery by 30-60 minutes.

"We are thrilled to be joining Beckman Coulter Diagnostics," said Eric Hamrock, Senior Director, CDS Service, Beckman Coulter Diagnostics and former CEO, StoCastic LLC. "Beckman Coulter will bring world-class market understanding and customer experience leadership, in addition to their commitment to supporting and building upon StoCastic's customers' success, making this a perfect fit for our organization."

"With the StoCastic acquisition, we combine Beckman Coulter Diagnostics biomarkers with TriageGo's evidence-based CDS to generate advanced decision support insights. This will enable clinicians to make informed decisions sooner and further improve patient outcomes," said Kelly Sager, Vice President and General Manager, CDS Solutions at Beckman Coulter Diagnostics.

Related Links:
Beckman Coulter, Inc. 
StoCastic, LLC 

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)

Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more